Renaissance Technologies LLC Sells 59,900 Shares of Prestige Consumer Healthcare Inc. $PBH

Renaissance Technologies LLC lessened its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 62.0% during the 1st quarter, HoldingsChannel reports. The institutional investor owned 36,702 shares of the company’s stock after selling 59,900 shares during the period. Renaissance Technologies LLC’s holdings in Prestige Consumer Healthcare were worth $2,175,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in PBH. UMB Bank n.a. raised its position in Prestige Consumer Healthcare by 110.1% in the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after purchasing an additional 219 shares in the last quarter. Bayforest Capital Ltd acquired a new stake in Prestige Consumer Healthcare during the fourth quarter valued at approximately $29,000. Torren Management LLC acquired a new stake in Prestige Consumer Healthcare during the fourth quarter valued at approximately $35,000. Caitong International Asset Management Co. Ltd grew its stake in shares of Prestige Consumer Healthcare by 69.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 574 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Prestige Consumer Healthcare in the 3rd quarter valued at approximately $37,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on PBH. Oppenheimer downgraded Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, June 25th. Finally, Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $70.75.

Prestige Consumer Healthcare Stock Performance

PBH stock opened at $52.79 on Tuesday. The company has a 50 day moving average price of $48.96 and a 200 day moving average price of $55.91. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $71.07. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The stock has a market capitalization of $2.50 billion, a PE ratio of 14.79, a price-to-earnings-growth ratio of 1.70 and a beta of 0.34.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.09. The firm had revenue of $265.71 million for the quarter, compared to analyst estimates of $253.02 million. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The business’s quarterly revenue was up 6.5% compared to the same quarter last year. During the same period last year, the company earned $0.90 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.6 EPS for the current year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).